Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form showing they understand what the study involves and are willing to take part.
• People aged 18 years or older.
• People whose general physical health and ability to carry out daily activities falls within a certain range, as assessed by a doctor using a standard scale called the ECOG scale (scores 0–2, meaning fully active to capable of limited self-care — confirm with trial site).
• People who have been diagnosed with non-small cell lung cancer (a type of lung cancer) at an early to intermediate stage (Stage I, II, or III), confirmed by a biopsy.
• People whose lung cancer has been assessed by a doctor as not suitable for surgery, or who have chosen not to have surgery.
• People who have not received systemic cancer treatments (such as chemotherapy) within the 4 weeks before the injection, and who have had no more than one course of such treatment before starting radiation therapy.
• People whose tumour(s) can be reached for injection using a bronchoscope (a thin tube passed into the airways) or a CT scan-guided needle, as determined by the treating doctor.
• People with up to 4 lung lesions (including the main tumour and any affected lymph nodes) that can be injected and then treated with radiation.
• People whose tumour(s) can be measured on standard imaging scans, with affected lymph nodes measuring at least 15mm on the short side on a CT or MRI scan.
• People whose blood and organ function test results meet the required levels, including adequate red blood cells, white blood cells, platelets, kidney function, liver function, and protein levels in the blood (confirm specific values with trial site).
• Women who could potentially become pregnant must have a negative pregnancy test within 7 days before the injection.

Who may not be able to join:

• People whose tumour cannot be reached for injection via bronchoscope or CT-guided needle.
• People who are unable to receive radiation therapy for any reason.
• Women who are pregnant or breastfeeding.
• Women who could potentially become pregnant, and their male partners, who are unwilling or unable to use a highly effective form of contraception throughout the entire study period (one with a failure rate of less than 1% per year when used correctly and consistently).
• People for whom the treating doctor believes taking part would not be in their best interest or could affect their wellbeing.
• People with a past medical history of interstitial lung disease (scarring or inflammation of lung tissue), lung inflammation caused by medication, or previous radiation treatment to the lungs or other organs in the chest (note: prior breast radiation may be acceptable — confirm with trial site).
• People who have received any approved or experimental cancer treatment or immunotherapy within 4 weeks before the injection.
• People who have already received more than one course of systemic cancer treatment before starting radiation therapy.
• People currently receiving systemic cancer treatments such as chemotherapy, immunotherapy, or targeted therapy, or who are taking part in another therapeutic clinical trial at the same time.
• People with a known allergy or medical reason to avoid iodine-based or gadolinium-based contrast dyes used in scans.
• People with another active cancer, with some exceptions for certain cancers that have been fully treated and have not returned (confirm with trial site).
• People with serious uncontrolled illnesses such as active infection, recent severe lung infection, heart failure, unstable chest pain, kidney failure, heart rhythm problems, or a psychiatric condition that could affect their ability to follow the treatment plan.
• People with known active, uncontrolled HIV, hepatitis B, or hepatitis C infection.
• People with significant cognitive impairment.

Important: Always verify eligibility with the trial site directly before applying.